Appili Therapeutics

Appili Therapeutics Inc is an anti-infective pharmaceuticals development company.In March 2023, Appili Therapeutics Inc entered into an amended and restated secured loan agreement with Long Zone Holdings Inc to provide Appili a second tranche loan in the amount of C$2.5 million.In May 2022, Appili Therapeutics Inc had priced its previously announced overnight marketed offering of equity securities to issue 50,000,000 units at C$0.09 per unit to raise C$4,500,000. Later that month, Appili Therapeutics Inc closed its previously announced public offering of 50,000,000 Units at $0.09 per Unit raising $4,500,000.In October 2021, Appili Therapeutics Inc had closed public offering of $7,000,220.In October 2021, Appili Therapeutics Inc had priced its previously announced overnight marketed offering of equity securities to issue 8,434,000 units at C$0.83 per Unit to raise C$7,000,220.In August 2021, Appili Therapeutics Inc had closed its $3.5 million convertible se